Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
LGND Ligand Pharmaceuticals	$114.64 +1.9%	$106.50	$77.53 ▼ $129.90	$2.21B	0.83	116,852 shs	144,654 shs
NAMS NewAmsterdam Pharma	$18.20 -1.6%	$18.45	$14.06 ▼ $27.29	$2.04B	-0.03	694,190 shs	633,421 shs
SBTX Silverback Therapeutics	$15.91 +7.4%	$14.27	$2.80 ▼ $8.97	$573.68M	0.6	337,931 shs	2.73 million shs
SRPT Sarepta Therapeutics	$20.77 -3.7%	$43.71	$18.30 ▼ $173.25	$2.04B	0.61	2.06 million shs	7.51 million shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
LGND Ligand Pharmaceuticals	+1.87%	-0.65%	+8.86%	+4.78%	+42.34%
NAMS NewAmsterdam Pharma	-1.57%	-11.22%	-4.36%	-24.39%	+6.37%
SBTX Silverback Therapeutics	-2.24%	+0.88%	+8.97%	+27.21%	+83.42%
SRPT Sarepta Therapeutics	-3.66%	-45.07%	-45.26%	-71.72%	-82.33%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
LGND Ligand Pharmaceuticals	4.4207 of 5 stars	3.5	0.0	0.0	4.4	2.7	3.3	1.9
NAMS NewAmsterdam Pharma	3.009 of 5 stars	3.5	2.0	0.0	0.0	2.6	5.0	0.0
SBTX Silverback Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SRPT Sarepta Therapeutics	4.5512 of 5 stars	4.3	2.0	0.0	4.2	1.5	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
LGND Ligand Pharmaceuticals	3.00	Buy	$146.14	27.48% Upside
NAMS NewAmsterdam Pharma	3.00	Buy	$42.89	135.65% Upside
SBTX Silverback Therapeutics	0.00	N/A	N/A	N/A
SRPT Sarepta Therapeutics	2.54	Moderate Buy	$70.76	240.68% Upside

Current Analyst Ratings Breakdown

Latest SBTX, SRPT, LGND, and NAMS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/18/2025	SRPT Sarepta Therapeutics	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$85.00 ➝ $40.00
6/18/2025	SRPT Sarepta Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$24.00
6/17/2025	NAMS NewAmsterdam Pharma	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$42.00
6/17/2025	SRPT Sarepta Therapeutics	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$50.00 ➝ $25.00
6/17/2025	SRPT Sarepta Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$29.00
6/17/2025	SRPT Sarepta Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$60.00 ➝ $30.00
6/17/2025	SRPT Sarepta Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$100.00 ➝ $75.00
6/17/2025	SRPT Sarepta Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$89.00 ➝ $29.00
6/17/2025	SRPT Sarepta Therapeutics	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Peer Perform
6/16/2025	SRPT Sarepta Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$125.00 ➝ $54.00
6/16/2025	SRPT Sarepta Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$113.00 ➝ $40.00

(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
LGND Ligand Pharmaceuticals	$167.13M	13.23	$1.61 per share	71.35	$43.95 per share	2.61
NAMS NewAmsterdam Pharma	$45.56M	44.85	N/A	N/A	$8.20 per share	2.22
SBTX Silverback Therapeutics	N/A	N/A	N/A	N/A	$7.41 per share	N/A
SRPT Sarepta Therapeutics	$1.90B	1.07	$2.43 per share	8.53	$15.99 per share	1.30

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
LGND Ligand Pharmaceuticals	-$4.03M	-$7.12	N/A	30.90	N/A	-73.07%	-7.83%	-6.92%	8/5/2025 (Estimated)
NAMS NewAmsterdam Pharma	-$241.60M	-$1.88	N/A	N/A	N/A	-397.45%	-37.34%	-33.45%	8/6/2025 (Estimated)
SBTX Silverback Therapeutics	-$89.48M	-$2.42	N/A	∞	N/A	N/A	-29.62%	-28.20%	N/A
SRPT Sarepta Therapeutics	$235.24M	-$2.69	N/A	1.90	N/A	-11.12%	-14.88%	-5.12%	8/6/2025 (Estimated)

Latest SBTX, SRPT, LGND, and NAMS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	LGND Ligand Pharmaceuticals	$1.23	$1.33	+$0.10	-$2.21	$37.84 million	$45.33 million
5/8/2025	Q1 2025	NAMS NewAmsterdam Pharma	-$0.45	-$0.49	-$0.04	-$0.34	$1.46 million	$2.98 million
5/6/2025	Q1 2025	SRPT Sarepta Therapeutics	$2.20	-$3.42	-$5.62	-$4.60	$685.75 million	$744.86 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
LGND Ligand Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NAMS NewAmsterdam Pharma	N/A	N/A	N/A	N/A	N/A
SBTX Silverback Therapeutics	N/A	N/A	N/A	N/A	N/A
SRPT Sarepta Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
LGND Ligand Pharmaceuticals	N/A	5.27	5.02
NAMS NewAmsterdam Pharma	N/A	19.98	19.98
SBTX Silverback Therapeutics	N/A	67.87	67.87
SRPT Sarepta Therapeutics	1.00	4.02	2.46

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
LGND Ligand Pharmaceuticals	91.28%
NAMS NewAmsterdam Pharma	89.89%
SBTX Silverback Therapeutics	74.89%
SRPT Sarepta Therapeutics	86.68%

Insider Ownership

Company	Insider Ownership
LGND Ligand Pharmaceuticals	7.00%
NAMS NewAmsterdam Pharma	20.84%
SBTX Silverback Therapeutics	34.40%
SRPT Sarepta Therapeutics	7.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
LGND Ligand Pharmaceuticals	80	19.29 million	17.94 million	Optionable
NAMS NewAmsterdam Pharma	4	112.27 million	88.87 million	Optionable
SBTX Silverback Therapeutics	83	36.06 million	23.65 million	Not Optionable
SRPT Sarepta Therapeutics	1,372	98.28 million	90.71 million	Optionable

SBTX, SRPT, LGND, and NAMS Headlines

Recent News About These Companies

What’s next for Sarepta Therapeutics with gene therapy under fire?

June 19 at 11:10 AM | statnews.com

Deutsche Bank Aktiengesellschaft Issues Pessimistic Forecast for Sarepta Therapeutics (NASDAQ:SRPT) Stock Price

June 19 at 4:03 AM | americanbankingnews.com

Sarepta Therapeutics (NASDAQ:SRPT) Rating Lowered to Hold at The Goldman Sachs Group

June 19 at 4:03 AM | americanbankingnews.com

Sarepta Therapeutics (NASDAQ:SRPT) Price Target Lowered to $75.00 at Wells Fargo & Company

June 19 at 1:43 AM | americanbankingnews.com

Sarepta Therapeutics Target of Unusually High Options Trading (NASDAQ:SRPT)

June 19 at 1:11 AM | americanbankingnews.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT

June 18 at 12:42 PM | globenewswire.com

Sarepta Drops 42% on Fatalities; Markets Eye Solid Biosciences (SRPT)

June 18 at 11:39 AM | marketbeat.com

Mizuho Lowers Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $40.00

June 18 at 11:23 AM | marketbeat.com

Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Down 3% After Analyst Downgrade

June 18 at 10:39 AM | marketbeat.com

Sarepta Stock (SRPT) Could Soar 200% Despite Growing Caution on Wall Street

June 18 at 10:17 AM | tipranks.com

SRPT NOTICE: Did Sarepta Therapeutics, Inc. Mislead Investors about the Safety of Elevidys? Contact BFA Law if You Lost Money (NASDAQ:SRPT)

June 18 at 8:38 AM | globenewswire.com

Sarepta Therapeutics (NASDAQ:SRPT) Downgraded to "Hold" Rating by TD Cowen

June 18 at 8:05 AM | marketbeat.com

Robert W. Baird Has Lowered Expectations for Sarepta Therapeutics (NASDAQ:SRPT) Stock Price

June 18 at 2:58 AM | americanbankingnews.com

Sarepta Therapeutics (NASDAQ:SRPT) Stock Rating Lowered by BMO Capital Markets

June 18 at 2:25 AM | americanbankingnews.com

Sarepta Therapeutics (NASDAQ:SRPT) Downgraded by HC Wainwright to Sell

June 18 at 2:25 AM | americanbankingnews.com

Sarepta Therapeutics (NASDAQ:SRPT) Given "Neutral" Rating at Cantor Fitzgerald

June 18 at 1:51 AM | americanbankingnews.com

Sarepta Therapeutics (NASDAQ:SRPT) Given Equal Weight Rating at Morgan Stanley

June 18 at 1:51 AM | americanbankingnews.com

Jefferies Financial Group Lowers Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $54.00

June 18 at 1:51 AM | americanbankingnews.com

Sarepta Therapeutics (NASDAQ:SRPT) Reaches New 12-Month Low After Analyst Downgrade

June 18 at 1:12 AM | americanbankingnews.com

Sarepta Therapeutics: Overcoming Challenges and Capturing Growth Opportunities Amid Elevidys Setback

June 17 at 7:24 PM | tipranks.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT

June 17 at 7:08 PM | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SBTX, SRPT, LGND, and NAMS Company Descriptions

Ligand Pharmaceuticals NASDAQ:LGND

$114.64 +2.10 (+1.87%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$114.47 -0.17 (-0.15%)

As of 06/18/2025 06:07 PM Eastern

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.

NewAmsterdam Pharma NASDAQ:NAMS

$18.20 -0.29 (-1.57%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$18.46 +0.26 (+1.43%)

As of 06/18/2025 07:12 PM Eastern

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Silverback Therapeutics NASDAQ:SBTX

$15.91 +1.09 (+7.35%)

As of 06/18/2025

Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Sarepta Therapeutics NASDAQ:SRPT

$20.77 -0.79 (-3.66%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$20.68 -0.09 (-0.41%)

As of 06/18/2025 07:59 PM Eastern

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time